Results 91 to 100 of about 11,727 (181)

Requirement of the Jak2 tyrosine kinase in Bcr -Abl oncogenic transformation

, 2002
Philadelphia chromosome (Ph)-positive chronic myeloid leukemia is caused by a clonal myeloproliferative expansion of malignant primitive hematopoietic progenitor cells.
Xie, Shanhai
core  

Multimodal gene and targeted drug therapy for chronic myelogenous leukemia using BIM/MCL-1 chimeric nanoparticle: computational target analysis and therapeutic validation. [PDF]

Nano Converg
Lugin ML, Lei W, Lee RT, Chung JY, Katritsis NM, Hwang W, Fleischman AG, Han N, Kwon YJ.   +8 more
europepmc   +1 more source

The PML-RAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patients

, 2001
Background and Objectives. Detection of PML-RAR alpha transcripts by RT-PCR is now established as a rapid and sensitive method for diagnosis of acute promyelocytic leukemia (APL), Although the majority of patients in longterm clinical remission are ...
Gameiro, P, Diamond, J, Foroni, L, Silva, AL, Mehta, AB, Prentice, HG, Carrara, P, Vieira, S, Guimaraes, JE, Parreira, A, Hoffbrand, AV, de Sousa, AB   +11 more
core  

Roles of extracellular vesicles in the pathogenesis of chronic myeloid leukemia. [PDF]

J Physiol Biochem
Hrdinova T, Kupcova Skalnikova H.
europepmc   +1 more source

HIRA-SETDB1-H3K9me3 axis regulates chromatin architecture in leukemia cells. [PDF]

J Biol Chem
Shirude MB, Devarajan A, Sahu SA, Mukherjee A, Dutta D.   +4 more
europepmc   +1 more source

Phosphorylation activity and specificity of the oncogenic tyrosine kinase fusion protein BCR/ABL

Dissertation Karl-Franzens-Universität Graz ...
openaire   +1 more source

The isolation and characterisation of MHC-presented peptides from CML-derived cell-lines, with a focus on post-translational modification

, 2011
Phosphorylation is a key regulator of protein function and activity, and aberrant kinase activity is implicated in a wide range of malignancies, of which the bcr:abl fusion kinase found in chronic myeloid leukaemia is a classic example.
Kapoor, KN
core  

Targeting Mitochondrial Vulnerabilities in Chronic Myeloid Leukemia: From Pathobiology to Novel Therapeutic Opportunities. [PDF]

Cancers (Basel)
Caprino F, Valentino I, Bruzzese A, Ganino L, Mesuraca M, Citraro R, Gentile M, Gallo Cantafio ME, Amodio N.   +8 more
europepmc   +1 more source

Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design. [PDF]

Circulation
Jambon-Barbara C, Suissa S, Dell'Aniello S, Hlavaty A, Cracowski JL, Chaumais MC, Humbert M, Montani D, Khouri C.   +8 more
europepmc   +1 more source

How chronic myeloid leukaemia inhibitors influence Bcr-Abl interactions with its partner protein CrkII

, 2011
The pathology of chronic myeloid leukaemia (CML) is tightly connected with the Bcr-Abl fusion protein and its molecular network [1]. Its network has been recently solved [2] and opened a possibility for new approach to drug discovery, where drug targets ...
Nayak, Jeremie
core